Another good move in the pps today on rising volume going into earnings in February. News about severe flu season is a good indicator of another strong quarter in sales and earnings in the first three months of the New Year. I expect the past 4th quarter eps will easily beat the street's estimates and guidance should be good for the rest of the year if the C. difficile molecular test ramps up sales for the quarters following the flu season. It would not surprise me if the new analyst coverage from the larger brokerages e.g. JP Morgan, and Piper, upgrades the stock and raises the price targets significantly if the conference call gives them a positive spin on top and bottom line growth in the coming two years. If the company delievers on the growth, it may be a target for acquisition by a larger diagnostic company looking to enter the molecular space with an established market that they can expand. e.g. ABT.